CA2899811A1 - Anticorps anti-mucines permettant la detection precoce et le traitement du cancer du pancreas - Google Patents

Anticorps anti-mucines permettant la detection precoce et le traitement du cancer du pancreas Download PDF

Info

Publication number
CA2899811A1
CA2899811A1 CA2899811A CA2899811A CA2899811A1 CA 2899811 A1 CA2899811 A1 CA 2899811A1 CA 2899811 A CA2899811 A CA 2899811A CA 2899811 A CA2899811 A CA 2899811A CA 2899811 A1 CA2899811 A1 CA 2899811A1
Authority
CA
Canada
Prior art keywords
antibody
seq
antibodies
pancreatic cancer
muc5ac
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2899811A
Other languages
English (en)
Inventor
Donglin Liu
David V. Gold
Chien-Hsing Chang
Serengulam V. Govindan
David M. Goldenberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunomedics Inc
Original Assignee
Immunomedics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/036,765 external-priority patent/US8795662B2/en
Application filed by Immunomedics Inc filed Critical Immunomedics Inc
Publication of CA2899811A1 publication Critical patent/CA2899811A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4725—Mucins, e.g. human intestinal mucin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2899811A 2013-04-01 2014-04-01 Anticorps anti-mucines permettant la detection precoce et le traitement du cancer du pancreas Abandoned CA2899811A1 (fr)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201361807176P 2013-04-01 2013-04-01
US61/807,176 2013-04-01
US201361818708P 2013-05-02 2013-05-02
US61/818,708 2013-05-02
US14/036,765 US8795662B2 (en) 2002-06-14 2013-09-25 Anti-mucin antibodies for early detection and treatment of pancreatic cancer
US14/036,765 2013-09-25
US201361896909P 2013-10-29 2013-10-29
US61/896,909 2013-10-29
PCT/US2014/032513 WO2014165506A1 (fr) 2013-04-01 2014-04-01 Anticorps anti-mucines permettant la détection précoce et le traitement du cancer du pancréas

Publications (1)

Publication Number Publication Date
CA2899811A1 true CA2899811A1 (fr) 2014-10-09

Family

ID=51659171

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2899811A Abandoned CA2899811A1 (fr) 2013-04-01 2014-04-01 Anticorps anti-mucines permettant la detection precoce et le traitement du cancer du pancreas

Country Status (4)

Country Link
EP (1) EP2981829A4 (fr)
CN (1) CN105074469A (fr)
CA (1) CA2899811A1 (fr)
WO (1) WO2014165506A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2948013A1 (fr) * 2014-06-30 2016-01-07 Immunomedics, Inc. Anticorps reagissant avec un epitope situe dans la region n-terminale de muc5ac comprenant un sous-domaine 2 riche en cysteine (cys2)
CN105738492B (zh) * 2014-12-10 2017-12-19 人福医药集团股份公司 Lc‑ms/ms联用测定拉帕替尼中杂质含量的方法
JP7063623B2 (ja) 2015-04-20 2022-05-09 グリザリックス リミテッド 治療用抗体およびその使用
WO2016176332A1 (fr) * 2015-04-27 2016-11-03 The Regents Of The University Of Colorado Promédicaments d'anthracyne et procédés de production et d'utilisation de ces derniers
US20170007727A1 (en) * 2015-07-07 2017-01-12 Immunomedics, Inc. METHODS OF IMAGING WITH Ga-68 LABELED MOLECULES
AU2016361350B2 (en) * 2015-11-23 2023-04-06 Sangamo Therapeutics, Inc. Methods and compositions for engineering immunity
CN107362370B (zh) * 2016-05-13 2022-07-26 国家纳米科学中心 一种基于金纳米簇联合NGF siRNA治疗胰腺癌的方法
ES2858151T3 (es) 2016-05-20 2021-09-29 Hoffmann La Roche Conjugados de PROTAC-anticuerpo y procedimientos de uso
CN107153908A (zh) * 2017-03-24 2017-09-12 国家计算机网络与信息安全管理中心 移动新闻App影响力评级方法
CN113198018A (zh) * 2021-04-30 2021-08-03 张志刚 靶向白三烯受体在胰腺癌治疗组合物中的应用
CN116804221B (zh) * 2023-08-23 2023-11-03 汲迈生命科技(苏州)有限公司 Lmo7表达水平在预测胰腺癌吉西他滨耐药中的应用
CN117275744B (zh) * 2023-11-22 2024-02-13 北京大学人民医院 一种综合基因突变特征与mIF图像特征的肺癌预后多模态预测模型构建方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0311799A (pt) * 2002-06-14 2005-05-10 Immunomedics Inc Anticorpo monoclonal hpam4
US9005613B2 (en) * 2003-06-16 2015-04-14 Immunomedics, Inc. Anti-mucin antibodies for early detection and treatment of pancreatic cancer
WO2010017500A2 (fr) * 2008-08-08 2010-02-11 Immunomedics, Inc. Anticorps anti-cancer pancréatique
WO2011082321A1 (fr) * 2009-12-31 2011-07-07 Van Andel Research Institute Procédés de diagnostic du potentiel de malignité de lésions kystiques pancréatiques
EP2526421B1 (fr) * 2010-01-22 2018-11-21 Immunomedics, Inc. Détection d'un adénocarcinome pancréatique à un stade précoce
WO2011133609A2 (fr) * 2010-04-19 2011-10-27 The Translational Genomics Research Institute Méthodes et nécessaires de prédiction de résultat thérapeutique associée à l'utilisation d'inhibiteurs de la btk
US8962804B2 (en) * 2010-10-08 2015-02-24 City Of Hope Meditopes and meditope-binding antibodies and uses thereof
WO2012048332A2 (fr) * 2010-10-08 2012-04-12 John Williams Interface de liaison d'un réseau d'anticorps monoclonaux pour méditopes, systèmes d'administration de méditopes et leurs procédés d'utilisation
CA2827076A1 (fr) * 2011-02-15 2012-08-23 Immumomedics, Inc. Anticorps anti-mucines permettant la detection precoce et le traitement du cancer du pancreas

Also Published As

Publication number Publication date
EP2981829A1 (fr) 2016-02-10
CN105074469A (zh) 2015-11-18
EP2981829A4 (fr) 2016-10-26
WO2014165506A1 (fr) 2014-10-09

Similar Documents

Publication Publication Date Title
US9238084B2 (en) Anti-mucin antibodies for early detection and treatment of pancreatic cancer
US9089618B2 (en) Anti-mucin antibodies for early detection and treatment of pancreatic cancer
US8491896B2 (en) Anti-pancreatic cancer antibodies
CA2731438C (fr) Anticorps anti-cancer pancreatique
US9513293B2 (en) Detection of early-stage pancreatic adenocarcinoma
CA2899811A1 (fr) Anticorps anti-mucines permettant la detection precoce et le traitement du cancer du pancreas
US9452228B2 (en) Antibodies reactive with an epitope located in the N-terminal region of MUC5AC comprising cysteine-rich subdomain 2 (Cys2)
CA2948013A1 (fr) Anticorps reagissant avec un epitope situe dans la region n-terminale de muc5ac comprenant un sous-domaine 2 riche en cysteine (cys2)
US8974784B2 (en) Anti-pancreatic cancer antibodies
US9599619B2 (en) Anti-pancreatic cancer antibodies
US20170137534A1 (en) Anti-Pancreatic Cancer Antibodies

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20190403